4 August 2021 in PLOS Computational Biology
Modeling the impact of amino acid mutations on protein-protein interaction plays a crucial role in protein engineering and drug design. In this study, we develop GeoPPI, a novel structure-based deep-learning framework to predict the change of binding affinity upon mutations. Based on the three-dimensional structure of a protein, GeoPPI first learns a geometric representation that encodes topology features of the protein structure via a self-supervised learning scheme. These representations are then used as features for training gradient-boosting trees to predict the changes of protein-protein binding affinity upon mutations. We find that GeoPPI is able to learn meaningful features that characterize interactions between atoms in protein structures. In addition, through extensive experiments, we show that GeoPPI achieves new state-of-the-art performance in predicting the binding affinity changes upon both single- and multi-point mutations on six benchmark datasets. Moreover, we show that GeoPPI can accurately estimate the difference of binding affinities between a few recently identified SARS-CoV-2 antibodies and the receptor-binding domain (RBD) of the S protein. These results demonstrate the potential of GeoPPI as a powerful and useful computational tool in protein design and engineering. Our code and datasets are available at: https://github.com/Liuxg16/GeoPPI. Estimating the binding affinities of protein-protein interactions (PPIs) is crucial to understand protein function and design new functional proteins. Since the experimental measurement in wet-labs is labor-intensive and time-consuming, fast and accurate in silico approaches have received much attention. Although considerable efforts have been made in this direction, predicting the effects of mutations on the protein-protein binding affinity is still a challenging research problem. In this work, we introduce GeoPPI, a novel computational approach that uses deep geometric representations of protein complexes to predict the effects of mutations on the binding affinity. The geometric representations are first learned via a self-supervised learning scheme and then integrated with gradient-boosting trees to accomplish the prediction. We find that the learned representations encode meaningful patterns underlying the interactions between atoms in protein structures. Also, extensive tests on major benchmark datasets show that GeoPPI has made an important improvement over the existing methods in predicting the effects of mutations on the binding affinity.
23 June 2022 in Nature Machine Intelligence
18 November 2024 in Bioinformatics
Accurate drug response prediction is critical to advancing precision medicine and drug discovery. Recent advances in deep learning (DL) have shown promise in predicting drug response; however, the lack of convenient tools to support such modeling limits their widespread application. To address this, we introduce DeepDR, the first DL library specifically developed for drug response prediction. DeepDR simplifies the process by automating drug and cell featurization, model construction, training, and inference, all achievable with brief programming. The library incorporates three types of drug features along with nine drug encoders, four types of cell features along with nine cell encoders, and two fusion modules, enabling the implementation of up to 135 DL models for drug response prediction. We also explored benchmarking performance with DeepDR, and the optimal models are available on a user-friendly visual interface. DeepDR can be installed from PyPI (https://pypi.org/project/deepdr). The source code and experimental data are available on GitHub (https://github.com/user15632/DeepDR). Supplementary data are available at Bioinformatics online.
6 August 2025 in Bioinformatics
Motivation: The structural complexities enable RNA to serve as a versatile molecular scaffold capable of binding small molecules with high specificity. Understanding these interactions is essential for elucidating RNA’s role in disease mechanisms and developing RNA-targeted therapeutics. However, predicting RNA-small molecule binding sites remains a significant challenge due to their conformational flexibility, structural diversity, and the limited availability of high-resolution structural data. Results: In this study, we propose RLsite, a novel computational framework integrating pre-trained RNA language models with Graph Attention Networks (GAT) to predict small-molecule binding sites on RNA. Our method effectively captures both sequential and structural features of RNA by leveraging large-scale RNA sequence data to learn intrinsic patterns and processing graph-based RNA structures to highlight key topological and spatial features. Compared to existing methods, RLsite demonstrates superior accuracy, generalizability, and biological relevance, achieving a Precision of 0.749, a Recall of 0.654, an MCC of 0.474, and an AUC of 0.828 on the public test set, which significantly outperforms the previous models, such as CapBind (an AUC of 0.770), MultiModRLBP (an AUC of 0.780), and RNABind (an AUC of 0.471). Notably, a case study of the PreQ1 riboswitch has achieved strong predictive performance (AUC = 0.97, Recall = 0.9), and its predicted binding sites have been confirmed experimentally. These results underscore our method as a potentially powerful tool for RNA-targeted drug discovery and advancing our understanding of RNA-ligand interactions. Availability and implementation: The resource codes and data can be accessed at https://github.com/SaisaiSun/RLsite. Supplementary information: Supplementary data are available at Bioinformatics online.
15 October 2025 in Bioinformatics
Motivation: Deep generative methods based on language models have the capability to generate new data that resemble a given distribution and have begun to gain traction in ligand design. However, existing models face significant challenges when it comes to generating ligands for unseen targets, a scenario known as zero-shot learning. The ability to effectively generate ligands for novel targets is crucial for accelerating drug discovery and expanding the applicability of ligand design. Therefore, there is a pressing need to develop robust deep generative frameworks that can operate efficiently in zero-shot scenarios. Results: In this study, we introduce ZeroGEN, a novel zero-shot deep generative framework based on protein sequences. ZeroGEN analyzes extensive data on protein–ligand inter-relationships and incorporates contrastive learning to align known protein-ligand features, thereby enhancing the model’s understanding of potential interactions between proteins and ligands. Additionally, ZeroGEN employs self-distillation to filter the initially generated data, retaining only the ligands deemed reliable by the model. It also implements data augmentation techniques to aid the model in identifying ligands that match unseen targets. Experimental results demonstrate that ZeroGEN successfully generates ligands for unseen targets with strong affinity and desirable drug-like properties. Furthermore, visualizations of molecular docking and attention matrices reveal that ZeroGEN can autonomously focus on key residues of proteins, underscoring its capability to understand and generate effective ligands for novel targets. Availability and implementation: The source code and data of this work is freely available in the https://github.com/viko-3/ZeroGEN.
17 February 2026 in Communications Biology
Covalent drugs have long played an essential role in therapeutics, yet computational design approaches remain largely confined to virtual screening of existing libraries. Despite recent advances in deep generative models for drug discovery, methods specifically tailored to de novo covalent drug generation are still lacking. Here we introduce CovaGEN, a conditional latent diffusion framework for the de novo design of covalent inhibitors with enhanced drug-likeness and safety. CovaGEN generates ligands from a drug-like latent space while conditioning on target sequences and employing a classifier to guide the formation of desirable covalent warheads. A reinforcement learning strategy further optimizes the safety profiles of generated molecules. Experimental results demonstrate that CovaGEN effectively generates covalent drugs with the desired covalent warheads, exhibiting strong target protein affinity, favorable drug-likeness, and low toxicity. When applied to EGFR T790M and Mpro, the generated compounds exhibit higher probabilities of covalent binding. Overall, CovaGEN offers a pioneering approach for the de novo design of covalent inhibitors, advancing the discovery of covalent drugs with improved properties.